MAPT and Alzheimer disease: There is evidence from experimental studies that cortisol might exacerbate Aβ and tau pathology in the brain, while mifepristone, a glucocorticoid antagonist, can decrease cerebral Aβ and tau load in a mouse model of AD (Ouanes and Popp, 2019).